Concurrent cisplatin, 5-fluorouracil, leucovorin, and radiotherapy for invasive bladder cancer (Q44466532)

3 December 2017

title

Concurrent cisplatin, 5-fluorouracil, leucovorin, and radiotherapy for invasive bladder cancer (English)

1 reference

adaptive radiation therapy

3 December 2017

main subject

0 references

1 reference

1 reference

Wen-Cheng Chen

1

1 reference

3 December 2017

Chuag-Chi Liaw

2

1 reference

3 December 2017

Cheng-Keng Chuang

3

1 reference

3 December 2017

Miao-Fen Chen

4

1 reference

3 December 2017

Chih-Shou Chen

5

1 reference

3 December 2017

Paul Yann Lin

6

1 reference

3 December 2017

Phei-Lang Chang

7

1 reference

3 December 2017

Sheng-Hsien Chu

8

1 reference

3 December 2017

Chun-Te Wu

9

1 reference

3 December 2017

Ji-Hong Hong

10

1 reference

3 December 2017

language of work or name

English

0 references

publication date

1 July 2003

1 reference

International Journal of Radiation Oncology Biology Physics

3 December 2017

published in

1 reference

3 December 2017

volume

56

1 reference

3 December 2017

issue

3

1 reference

3 December 2017

page(s)

726-733

1 reference

Results of contemporary radical cystectomy for invasive bladder cancer: a clinicopathological study with an emphasis on the inadequacy of the tumor, nodes and metastases classification

3 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900124-X

7 January 2021

Biology and management of bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900124-X

7 January 2021

Radical cystectomy with or without prior irradiation in the treatment of bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900124-X

7 January 2021

Stage B () transitional cell carcinoma of bladder highly curable by radical cystectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900124-X

7 January 2021

Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900124-X

7 January 2021

Organ-sparing treatment of advanced bladder cancer: a 10-year experience

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900124-X

7 January 2021

Combined modality program with possible organ preservation for invasive bladder carcinoma: results of RTOG protocol 85-12

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900124-X

7 January 2021

Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900124-X

7 January 2021

Bladder preservation by combined modality therapy for invasive bladder cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900124-X

7 January 2021

Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900124-X

7 January 2021

Cisplatin, fluorouracil, and high-dose leucovorin for recurrent or metastatic head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900124-X

7 January 2021

Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900124-X

7 January 2021

Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900124-X

7 January 2021

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900124-X

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900124-X

7 January 2021

Combination cisplatin, 5-fluorouracil and radiation therapy for locally advanced unresectable or medically unfit bladder cancer cases: a Southwest Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900124-X

7 January 2021

Invasive bladder carcinoma: a pilot study of conservative treatment with accelerated radiotherapy and concomitant cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900124-X

7 January 2021

A phase II trial of methotrexate, cisplatin, 5-fluorouracil, and leucovorin in the treatment of invasive and metastatic urothelial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900124-X

7 January 2021

Prognostic significance of thymidylate synthase activity in bladder carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900124-X

7 January 2021

Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900124-X

7 January 2021

10.1016/S0360-3016(03)00124-X

Identifiers

DOI

1 reference

3 December 2017

1 reference